EP1438409A1 - Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif - Google Patents

Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif

Info

Publication number
EP1438409A1
EP1438409A1 EP02785313A EP02785313A EP1438409A1 EP 1438409 A1 EP1438409 A1 EP 1438409A1 EP 02785313 A EP02785313 A EP 02785313A EP 02785313 A EP02785313 A EP 02785313A EP 1438409 A1 EP1438409 A1 EP 1438409A1
Authority
EP
European Patent Office
Prior art keywords
dsrna
strand
nucleotides
virus
helicase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02785313A
Other languages
German (de)
English (en)
Inventor
Anja Krebs
Matthias John
Detlef Schuppan
Stefan Limmer
Roland Kreutzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Europe AG
Original Assignee
Ribopharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10160151A external-priority patent/DE10160151A1/de
Priority claimed from PCT/EP2002/000151 external-priority patent/WO2002055692A2/fr
Application filed by Ribopharma AG filed Critical Ribopharma AG
Priority to EP02785313A priority Critical patent/EP1438409A1/fr
Priority claimed from PCT/EP2002/011973 external-priority patent/WO2003035876A1/fr
Publication of EP1438409A1 publication Critical patent/EP1438409A1/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • the invention relates to the use of a double-stranded ribonucleic acid for the treatment of an infection with a (+) strand RNA virus and the use of such a ribonucleic acid for the production of a medicament, a medicament and a method for inhibiting the replication of a (+) - strand RNA virus.
  • DE 101 00 586 C1 discloses a method for inhibiting the expression of a target gene in a cell, in which an oligoribonucleotide with a double-stranded structure is introduced into the cell. One strand of the double-stranded structure is complementary to the target gene.
  • (+) Strand RNA viruses have an RNA as the carrier of the genetic information, on which protein synthesis can take place directly inside the cell. No transcription is required. Apart from a 3 'and a 5' untranslated region, the entire length of the virus genome is translated into a polyprotein. The individual, functionally active structural and non-structural proteins emerge from the polyprotein by cleavage. In the viral genome, the sequences of the structural proteins are followed by the sequences of the non-structural proteins.
  • the non-structural protein NS3 is an ultimate functional enzyme with a serine protease domain and NTPase and helicase activity.
  • the object of the present invention is to avoid the disadvantages of the prior art.
  • an effective use for treating an infection with a (+) strand RNA virus is to be provided.
  • a medicament for the treatment of an infection with a (+) strand RNA virus and a use for the production of such a medicament are to be provided.
  • a method for inhibiting the replication of a (+) strand RNA virus is to be provided.
  • a double-stranded ribonucleic acid for the treatment of an infection with a (+) strand RNA virus, a strand S1 of the dsRNA having a region which is at least partially complementary to a section of the translatable area of the virus genome.
  • the invention further relates to the use of such a dsRNA for the manufacture of a medicament for the treatment of an infection with a (+) strand RNA virus.
  • the section of the translatable region of the virus genome is arbitrary. Although the virus genome codes for numerous proteins, it is surprisingly sufficient for inhibiting the replication of the (+) strand RNA virus if a dsRNA is used with a strand S1 which is complementary to any section of the translatable region of the virus genome. Such dsRNA can permanently destroy the integrity of the viral RNA genome through RNA interference. It is therefore ideal for treating an infection with such a virus. The treatment leads to a permanent improvement in the disease.
  • the (+) strand RNA virus can be a hepatitis C virus (HCV).
  • HCV hepatitis C virus
  • the possibility of effective treatment is particularly important here because vaccination against hepatitis C viruses has not been possible until now. HCV infection can lead to serious illnesses in humans, especially chronic hepatitis, liver cirrhosis and liver cancer.
  • the dsRNA causes the (+) strand RNA of the (+) strand RNA virus to be cut enzymatically in the region of the section mentioned.
  • the areas located in front of the interface in the reading direction of the viral RNA can nevertheless be translated and at least partially lead to functional proteins.
  • the expression of these proteins is not necessarily inhibited.
  • the dsRNA is suitable for inhibiting the expression of a polyprotein encoded by the virus genome. The inhibition can also take place only partially, i.e. such that only a part of the complete polyprotein is expressed or so that the total amount of the polyprotein expressed is reduced.
  • the dsRNA is preferably suitable for inhibiting the expression of a functional protease or helicase encoded by the virus genome, in particular the HCV-NS3 helicase.
  • the section to which the strand S1 of the dsRNA is complementary can be arranged in the reading direction of the viral RNA before or in the region of the viral genome coding for the helicase.
  • the inhibition of viral helicase expression is Surprisingly particularly advantageous. This is because the inventors have found that the presence of the viral helicase reduces the replication-inhibiting effect of the dsRNA. By inhibiting the expression of the helicase, the effect of the dsRNA is stronger than in inhibiting the expression of other viral proteins.
  • the complementary region of the dsRNA can have fewer than 25, in particular 19 to 24, preferably 20 to 24, particularly preferably 21 to 23, in particular 22 or 23, nucleotides.
  • a dsRNA with this structure is particularly efficient in the treatment of the virus infection and in particular in the inhibition of the replication of the virus.
  • the strand S1 of the dsRNA can have less than 30, preferably less than 25, particularly preferably 21 to 24, in particular 23, nucleotides. The number of these nucleotides is also the number of the maximum possible base pairs in the dsRNA. Such a dsRNA is particularly stable intracellularly.
  • the dsRNA preferably has at least at one end of the dsRNA a single-stranded overhang formed from 1 to 4, in particular 2 or 3, nucleotides. Single-stranded overhangs reduce the stability of the dsRNA in blood, serum and cells and at the same time increase the replication-inhibiting effect of the dsRNA. It is particularly advantageous if the dsRNA has the overhang only at one end, in particular at its end which has the 3 'end of the strand S1. The other end is then smooth in the case of a dsRNA having two ends, ie without overhangs.
  • an overhang at one end of the dsRNA is sufficient to enhance the replication-inhibiting effect of the dsRNA, without lowering the stability to the same extent as by two overhangs.
  • a dsRNA with only one overhang has been found in both Cell culture media as well as in blood, serum and cells have been shown to be sufficiently stable and particularly effective. Inhibiting the replication of the viruses is particularly effective if the overhang is at the 3 'end of the strand S1.
  • the dsRNA has a strand S2 in addition to the strand S1, i.e. it is made up of two single strands.
  • the dsRNA is particularly effective if the strand S1 (antisense strand) has a length of 23 nucleotides, the strand S2 has a length of 21 nucleotides and the 3 'end of the strand S1 has a single-stranded overhang formed from two nucleotides.
  • the end of the dsRNA located at the 5 'end of the strand S1 is smooth.
  • the dsRNA can be present in a preparation which is suitable for inhalation, oral intake, infusion and injection, in particular for intravenous or intraperitoneal infusion or injection.
  • the preparation can, in particular exclusively, consist of a physiologically compatible solvent, preferably a physiological saline solution or a physiologically compatible buffer, and the dsRNA.
  • the physiologically compatible buffer can be a phosphate-buffered saline solution.
  • the dsRNA is preferably in a physiologically compatible solution, in particular a physiologically compatible buffer or a physiological saline solution, or of a micellar structure, preferably a liposome Virus capsid, enclosed in a capsoid or a polymeric nano or microcapsule or bound to a polymeric nano or microcapsule.
  • the physiologically compatible buffer can be a phosphate-buffered saline solution.
  • a micellar structure, a virus capsid, a capsoid or a polymeric nano- or microcapsule can facilitate the uptake of the dsRNA into infected cells.
  • the polymeric nano- or microcapsule consists of at least one biodegradable polymer, for example polybutyl cyanoacrylate.
  • the polymeric nano- or microcapsule can transport and release dsRNA contained in or bound to it in the body.
  • the dsRNA can be administered orally orally, by inhalation, infusion or injection, in particular intravenous or intraperitoneal infusion or injection.
  • the dsRNA is preferably used in a dosage of at most 5 mg, in particular at most 2.5 mg, preferably at most 200 ⁇ g, particularly preferably at most 100 ⁇ g, preferably at most 50 ⁇ g, in particular at most 25 ⁇ g, per kg of body weight and day. It has been shown that the dsRNA already in this dosage has an excellent effectiveness in treating an infection with a (+) - stranded RNA virus.
  • the invention further relates to a medicament for the treatment of an infection with a (+) strand RNA virus, the medicament containing a double-stranded ribonucleic acid (dsRNA), one strand S1 of which at least in sections to a section of the translatable region of the virus genome has complementary area.
  • the medicament is preferably present in at least one administration unit which contains the dsRNA in an amount which has a dosage of at most 5 mg, in particular at most 2.5 mg, preferably at most 200 ⁇ g, particularly preferably at most 100 ⁇ g, preferably at most 50 ⁇ g, in particular at most 25 ⁇ g, per kg of body weight and day.
  • the administration unit can be designed for a single administration or ingestion per day.
  • the entire daily dose is contained in one administration unit. If the administration unit is designed for repeated administration or ingestion per day, the dsRNA is contained therein in a correspondingly smaller amount that enables the daily dose to be reached.
  • the administration unit can also be designed for a single administration or ingestion for several days, e.g. B. by releasing the dsRNA over several days. The administration unit then contains a corresponding multiple of the daily dose.
  • a method for inhibiting the replication of a (+) strand RNA virus in a cell is also provided, at least one double-stranded ribonucleic acid (dsRNA) being introduced into the cell and one strand S1 of the dsRNA being one part of the translatable Has region of the virus genome at least partially complementary area.
  • dsRNA double-stranded ribonucleic acid
  • the invention also relates to a dsRNA, one strand S1 of which has a region which is at least partially complementary to a section of the translatable region of the genome of a (+) strand RNA virus.
  • HCV has a genome of approximately 9600 nucleotides. It codes for the structural proteins C, El and E2 and for the non-structural proteins NS2, NS3, NS4a, NS4b, NS5a and NS5b. Since molecular biological analyzes with HCV in cell culture are very difficult, the effect of dsRNA on viral gene sequences is examined using a non-pathogenic replacement system. For this purpose, the part of the viral genome coding for the structural proteins C, E1 and E2 has been replaced by a neomycin cassette which mediates neomycin resistance.
  • the modified viral genome is registered with the Gene Accession Number AJ242654 at the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Bethesda, MD 20894, USA. It has been transfected into HuH-7 liver cells (JCRB0403, Japanese Collection of Research Bioresources Cell Bank, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya-ku, Tokyo 158, Japan). It replicates in these cells in the presence of the neomycin analog G418 without causing infectious particles.
  • the system which enables the stable replication of the modified HCV genome (Lohmann et al. Science 285, (1999), page 110) is also referred to as the "replicon model" for hepatitis C viruses.
  • the dsRNAs used have the following sequences, designated SEQ ID NO: 1 to SEQ ID NO: 4 in the sequence listing:
  • dsRNAl which corresponds to a sequence from the region coding for NS3: S2: 5'- AGA CAG UCG ACÜ UCA GCC UGG-3 '(SEQ ID NO: 1) Sl: 3'-GG UCU GUC AGC UGA AGU CGG A -5' (SEQ ID NO: 2)
  • dsRNA2 which as a negative control without relation to the sequence of NS3 corresponds to the sequence of nucleotides 886-909 of the vector pEGFP-Cl, accession number U55763, NCBI:
  • S2 represents the sense strand and Sl the anti-sense strand, i.e. the sequence of strand S2 is identical to the corresponding sequence from the HCV.
  • the HuH-7 cells are cultured in the presence of 1 mg / ml of the antibiotic G418 in Dulbecco's modified Eagle's medium with 20% fetal calf serum.
  • 80,000 cells per well (3.5 cm diameter) of a 6-well plate were sown in 2 ml of medium.
  • "Fugene 6" catalog number 1814443
  • Sorefene 6 100 ⁇ l serum-free medium (SFM) were mixed with 5 ⁇ l Fugene 6 reagent in a reaction vessel and incubated for 5 min at RT.
  • dsRNA2 corresponds to approx. 0.1 ⁇ mol / 1 final concentration dsRNA2
  • 3 ⁇ g dsRNAl corresponds to approx. 0.1 ⁇ mol / 1 final concentration dsRNAl
  • 1.5 ⁇ g dsRNAl plus 1, 5 ⁇ g dsRNA2 corresponds to approx. 0.05 ⁇ mol / 1 final concentration dsRNAl
  • 300 ng dsRNAl plus 2.7 ⁇ g dsRNA2 corresponds to approx. 0.01 ⁇ mol / 1 final concentration dsRNAl.
  • the parent concentrations of dsRNAl and dsRNA2 were 20 ⁇ M each (corresponds to approx.
  • dsRNA The effect of dsRNA on the replication of the modified HCV genome was determined using quantitative PCR. About 36 hours after the transfection, the cells were unlocked and the RNA contained was removed using the PeqGold RNAPure kit from PEQLAB Biotechnologie GmbH, Carl-Thiersch-Str. 2 b, D-91052 Er Weg, order number 30-1010, insulated in accordance with the manufacturer's instructions.
  • RNA 100-1000 ng
  • 100 pmol oligo-dT primer or 50 pmol random primer were used as primers.
  • 10 ⁇ l RNA (100-1000 ng), 0.5 ⁇ l oligo dT primer (100 pmol) and 1 ⁇ l random primer (50 pmol) were incubated for 10 min at 70 ° C. and then briefly stored on ice.
  • TAMRA carboxy-tetra-methyl-rhodamine
  • NS3 probe 5 '-CAT TGT CGT AGC AAC GGA CGC TCT AAT GAC-3' (SEQ ID NO 5)
  • ß2-microglobulin is a constitutively expressed protein. The following were used for quantification:
  • ß2-microglobulin probe 5 -AAC CGT CAC CTG GGA CCG AGA CAT GTA-3 ⁇ (SEQ ID NO 8)
  • ß2-Microglobulin Primer 5 -CCG ATG TAT ATG CTT GCA GAG TTA A-3 ⁇ (SEQ ID NO 9)
  • the NS3 probe and the ⁇ 2-microglobulin probe each had a FAM label at the 5 'end and a TAMRA label at the 3' end.
  • HCV NS3 cDNA was determined as a ratio to the amount of ⁇ 2-MG cDNA and represented graphically in FIG. 1.
  • "pEGFP" represents the value determined by transfection with dsRNA2 (control) and "HCV 0.1 ⁇ mol / 1", “HCV 0.05 ⁇ mol / 1” and "HCV 0.01 ⁇ mol / 1" each by transfection 0.1 ⁇ mol / 1, 0.05 ⁇ mol / 1 and values determined for 0.01 ⁇ mol / 1 NS3-specific dsRNAl.
  • Transfection with dsRNAl resulted in about 60-fold inhibition at 0.1 ⁇ mol / 1, 0.05 ⁇ mol / 1 and at 0.01 ⁇ mol / 1 in the medium compared to transfection with the non-specific control dsRNA2.

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilisation d'un acide ribonucléique à double brin pour traiter une infection à virus à ARN à simple brin positif, un brin S1 de l'ARN à double brin possédant un domaine au moins partiellement complémentaire d'un segment du domaine pouvant être traduit du génome viral.
EP02785313A 2001-10-26 2002-10-25 Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif Withdrawn EP1438409A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02785313A EP1438409A1 (fr) 2001-10-26 2002-10-25 Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
DE10155280 2001-10-26
DE10155280 2001-10-26
DE10158411 2001-11-29
DE10158411 2001-11-29
DE10160151 2001-12-07
DE10160151A DE10160151A1 (de) 2001-01-09 2001-12-07 Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WOPCT/EP02/00151 2002-01-09
PCT/EP2002/000151 WO2002055692A2 (fr) 2001-01-09 2002-01-09 Procede d'inhibition de l'expression d'un gene cible et medicament destine a la therapie d'une maladie tumorale
PCT/EP2002/000152 WO2002055693A2 (fr) 2001-01-09 2002-01-09 Procede pour inhiber l'expression d'un gene cible
WOPCT/EP02/00152 2002-01-09
DE10235621 2002-08-02
DE10235621 2002-08-02
EP02785313A EP1438409A1 (fr) 2001-10-26 2002-10-25 Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif
PCT/EP2002/011973 WO2003035876A1 (fr) 2001-10-26 2002-10-25 Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif

Publications (1)

Publication Number Publication Date
EP1438409A1 true EP1438409A1 (fr) 2004-07-21

Family

ID=32601226

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02785313A Withdrawn EP1438409A1 (fr) 2001-10-26 2002-10-25 Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif

Country Status (1)

Country Link
EP (1) EP1438409A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055693A2 (fr) * 2001-01-09 2002-07-18 Ribopharma Ag Procede pour inhiber l'expression d'un gene cible

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055693A2 (fr) * 2001-01-09 2002-07-18 Ribopharma Ag Procede pour inhiber l'expression d'un gene cible

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03035876A1 *

Similar Documents

Publication Publication Date Title
WO2003035876A1 (fr) Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif
WO2003035869A1 (fr) Utilisation d'un acide ribonucleique double brin pour inhiber de maniere ciblee l'expression d'un gene cible determine
EP1144623B9 (fr) Methode et medicament destines a inhiber l'expression d'un gene donne
WO2003033700A1 (fr) Procede d'inhibition de la replication de virus
WO2003035083A1 (fr) Medicament destine a traiter une fibrose par interference d'arn
DE69729292T2 (de) Kurze externe führungssequenzen
DE69434931T2 (de) Methode zur selektiven inaktivierung der viralen replication
WO2003062432A1 (fr) Procede permettant d'augmenter l'efficacite d'un inhibiteur de l'activite d'une tyrosine kinase
WO2003035082A1 (fr) Medicament destine a inhiber l'expression d'un gene cible
WO2009138146A2 (fr) Nouveaux agents thérapeutiques pour le traitement de l'hépatite
WO2005033310A1 (fr) Composes dsrna pim-1-specifiques
EP1438409A1 (fr) Utilisation d'un acide ribonucleique a double brin pour traiter une infection a virus a arn a simple brin positif
EP1841461B1 (fr) Substance injectable pour le traitement cible de cellules ganglionnaires de la retine
EP1259263B1 (fr) Complexation d'arn, notamment de ribozymes, avec des polyethylenimines pour sa stabilisation et son introduction cellulaire
DE102010056610A1 (de) Pharmazeutische Zusammensetzung enthaltend L-DNA
EP2393504B1 (fr) Compositions pharmaceutiques renfermant un ribozyme pour le traitement des effets secondaires de spiegelmers
EP1438405A1 (fr) Utilisation d'un acide ribonucleique double brin pour inhiber de maniere ciblee l'expression d'un gene cible determine
EP1080192B1 (fr) Oligonucleotides antisens pour le traitement de cellules proliferantes
EP1438056A1 (fr) Medicament destine a traiter une fibrose par interference d'arn
DE69835525T2 (de) Verminderungsregulation der genexpression durch kolorektale verabreichung von synthetischen oligonukleotiden
WO1993022433A2 (fr) Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament
DE10350256A1 (de) PIM-1-spezifische siRNA-Verbindungen
DE102004038535A1 (de) Zelluläre Einschleusung von Nukleinsäurewirkstoffen
DE102005022290A1 (de) Hexanukleotid-Wirkstoffe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070503